The B/T subtype of mixed phenotype acute leukemia (B/T MPAL) is defined by co-expression of antigens of both B-and T-cell lineages on leukemic blasts. Although it has been suggested that multilineage antigen expression portends poor response to chemotherapy, the clinical characteristics and driver mutations that underlie the pathogenesis of this rare subtype of acute leukemia are scarcely known. We identified nine cases of B/T MPAL from multiple institutions and correlated clinical and immunophenotypic findings with next-generation sequencing data. We report that B/T MPAL commonly presents with lymphadenopathy in adolescence and young adulthood. While the tumors have diverse cytogenetic and genomic perturbations, recurrent acquired aberrations include mutations in the putative transcriptional regulator PHF6 and the JAK-STAT and Ras signaling pathways. Alterations were also identified in genes encoding hematopoietic transcription factors, cell cycle regulators/tumor suppressors, and chromatin modifying enzymes. The genomic landscape of B/T MPAL strongly resembles that of T-ALL subgroups associated with early developmental arrest, while genetic alterations that are common in B-ALL were rarely seen. Two-thirds of the patients responded to ALL-based chemotherapy with or without stem cell transplantation. Our observations lay the groundwork for further study of the unique biology and clinical trajectory of B/T MPAL.
(bilineal). The European Group for Immunological Characterization of
Acute Leukemias (EGIL) in 1995 proposed using a weighted score for each marker associated with myeloid, B-cell, and T-cell lineages to diagnose MPAL, which is defined as an acute leukemia with a score greater than 2 for more than one lineage. 4 The World Health Organization (WHO) classification in 2008 and 2016 emphasized fewer and more lineage-specific markers, such as CD19, CD79a, CD22, and CD10 for B lineage, CD3 for T lineage, myeloperoxidase (MPO) for myeloid lineage, and non-specific esterase, CD11c, CD14, CD64, and lysozyme for monocytic lineage. [5] [6] [7] Furthermore, cases that can be classified in another category, such as patients with t(8;21), t(15;17), inv, 16 FGFR1 mutations or translocations, blast phase of chronic myeloid leukemia, AML with myelodysplasia-related changes, and therapy-related AML were excluded. MPAL most commonly presents as a combination of B/myeloid or T/myeloid markers. The B/T subtype of MPAL is particularly rare and understudied.
B/T MPAL may define a high-risk subgroup of acute lymphoblastic leukemia (ALL), as multilineage protein expression often portends poor response to chemotherapy. Suggested reasons for poor outcomes include the intrinsic chemoresistance of primitive mixedphenotype blasts due to slow replication, outgrowth of resistant subclones that have undergone lineage switching, and expression of high levels of multidrug resistance proteins. 3, 8 Immunophenotype is an important diagnostic and prognostic factor in ALL as it informs treatment selection and probability of higher-risk disease. T-ALL, which represents 25% of cases, historically has worse outcomes in the pediatric population than B-ALL. 9, 10 Within T-ALL, the early T-cell precursor (ETP) subgroup is biologically distinctive and may be associated with poorer early response and higher rates of induction failure. The definition of ETP-ALL is based on the immunophenotype of the leukemic cells, which are typically CD1a−, CD8−, CD5− (dim), and positive for 1 or more stem cell or myeloid antigens. 10 As genomic features underlie the heterogeneity of disease, next-generation sequencing (NGS) has the potential to provide better classification and risk-stratification, guide patients to more appropriate gene-targeted or pathway-directed therapy, and identify novel targets for further investigation and drug development.
The current literature provides very limited insight into the clinical features and genomic landscape of B/T MPAL (Supplementary 
| Immunohistochemical stains
Immunohistochemical stains were performed as a part of routine clinical work-up. Antibodies against CD19, CD79a, CD22, CD10, CD20, and PAX5 (BSAP) were variably used to confirm B cell differentiation, and antibodies against CD3, CD1a, CD2, CD7, and CD56 were used to confirm concomitant T cell differentiation. Antibodies against MPO, CD33, lysozyme were used to exclude tumors with evidence of myelomonocytic differentiation.
| Cytogenetic analysis
Conventional chromosomal analysis was performed on G-banded metaphase cells prepared from unstimulated 24-and 48-h bone marrow aspirate cultures at the time of diagnosis using standard techniques. 16 The median number of metaphases analyzed was 20 (range, [20] [21] [22] [23] 
| Clonality assessment
Molecular minimal residual disease (MRD) assessment including rearrangement ofTRG, TRB, IGH, and/or IGK sequences from pretreatment samples was performed as previously described. 18, 19 Briefly, DNA was extracted from mononuclear cells in the diagnostic specimen and PCR for the detection of TCRG, TCRB, and IGH gene rearrangements was performed using standard primers. Clonal PCR products were identified using gel electrophoresis and were sequenced. normal cells at the end of induction therapy as previously described. 18 In cases where molecular MRD was not performed, MRD was assessed by percentage of blasts on flow cytometry as previously described. 3 | RESULTS
| B/T MPAL commonly presents with lymphadenopathy in adolescence and young adulthood
Our cohort of nine B/T MPAL patients included five males and four females, with a median age of diagnosis of 13 years (range, 3-57 years) ( Table 1 ). The most common presenting symptoms were fever (7 of 9 patients), fatigue (6 of 9 patients), and lymphadenopathy (6 of 9 patients), a notable finding as it is more characteristic of lymphoma than acute leukemia. There is no report of a mediastinal mass in any of these nine patients. PMH, past medical history; WBC, white blood cell; HGB, hemoglobin; HCT, hematocrit; PLT, platelet; PB, peripheral blood; BM; bone marrow; chemotherapy; BMT bone marrow transplantation; status, alive or dead; length of follow up, time followed from diagnosis. and PDGFRB, were negative for all patients. In addition, RT-PCR for common AML translocations performed in cases 6 and 7 was negative. are likely to be pathogenic. In this group, the most frequently mutated gene was PHF6 (5 of 9 cases), which encodes a plant homeodomain protein that has a putative role in chromatin regulation, In addition to single nucleotide variants, case 6 had a KTM2A-ELL fusion, which is characteristic of MPAL within the "MLL-rearranged" group and is associated with a unfavorable prognosis, [26] [27] [28] and case 9 had a SET-NUP214 fusion, which inhibits hematopoietic differentiation and promotes tumorigenesis through upregulation of HOXA cluster genes. 29, 30 An assay screening for recurrent kinase fusions in Philadelphia chromosome (Ph)-like ALL was performed on case 2 and was negative. Most cases had copy number variants consistent with their karyotype (Supporting Information Table 2 ). Notably, cases 1-3 had loss of function mutations involving the hematopoietic transcription factor genes ETV6 and IKZF1, cases 1-3 also had loss of cell cycle regulator/tumor suppressor genes RB1, CDKN1B, CDKN2A, cases 4 and 5 had gains of KMT2A (MLL) from trisomy 11, and case 7 had gain of CRLF2 on Xp22.33. Several other genetic aspects of case 7 also
| B/T MPAL is associated with frequent mutations in the putative chromatin modifier PHF6 and JAK-STAT and Ras signaling pathways
were of interest. Case 7 also had a gain of function mutation in IL7R, an event that frequently is seen in concert with CRLF2 abnormalities, which act together to stimulate the JAK-STAT pathway, as well as a strong gain of function mutations in NOTCH1, an abnormality that previously has been seen only in ETP-ALL and T-ALL. 31 Consistent with mixed B and T lineage phenotype, sequencing of B-and T-cell receptors revealed clonal TCRG and IGH rearrangements in case 2, IGK rearrangements in case 8, and TCRG rearrangements in case 9 (Supporting Information Table 3 ). One additional case, case 7, was tested and negative for clonal antigen receptor gene rearrangements. All other patients were not tested for clonality.
| Many B/T MPALs respond well to ALL-based, high-risk therapies
The patients in our study were diagnosed between 2011 and 2017.
All patients received some form of ALL-based therapy and 4 patients additionally underwent hematopoietic stem cell transplant (HSCT) ( Table 2 
